-
FDA News | VEGFR TKI Breaks Through Refractory Renal Cell Carcinoma!
Time of Update: 2021-03-22
On March 10, 2021, tivozanib was approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC).
-
Professor Wang Liwei: Progress in medical treatment of liver cancer
Time of Update: 2021-03-22
02 During the 2020 ASCO conference, a phase III study of apatinib versus placebo in the second-line treatment of Chinese patients with advanced liver cancer was announced.
-
The essence of the March 5, 2021 issue of Science
Time of Update: 2021-03-22
html" target="_blank">Science: New research has identified a variety of cardiac progenitor cell populations in the mouse embryonic heart region doi:10.
html" target="_blank">Science: New research has identified multiple cardiac progenitor cell populations in mouse embryonic heart regions doi:10.
-
Apatamide + ADT in the treatment of high-risk/high-tumor-burden mHSPC patients has a rapid, deep, and lasting decrease in PSA, and significant benefits for 4 years!
Time of Update: 2021-03-22
*For medical professionals to read only for reference, high-risk/high-tumor-burden mHSPC patients receive apatamide treatment, the PSA level decreases rapidly, deeply, and lastingly, with significant curative effect and good safety.
-
Breast cancer death risk increased by 85%!
Time of Update: 2021-03-22
Recently, a study conducted by researchers at the State University of New York at Buffalo (University at Buffalo) found that regular consumption of sugar-sweetened beverages can also increase the risk of death for breast cancer patients, including all causes (caused by various causes) The risk of death and the risk of specific (caused by breast cancer) death.
-
Summary of information on immunosuppressants in my country and recommendations
Time of Update: 2021-03-22
Copyright information This article is written or commissioned by the editorial department of Yijia Medical Course.
org.
Unauthorized use of article content and part of the content is an infringement, and the copyright owner reserves the right to pursue legal liabilities.
-
ROS1 targeted therapy drug resistance mechanism revealed; new targeted drugs have considerable efficacy in the treatment of indolent lymphoma | Cancer Information
Time of Update: 2021-03-22
CCR: ROS1 fusion patients undergo targeted therapy, and the main cause of resistance is ROS1 mutation 01JCO: Nano Wuliyuumab + ipilimumab maintenance treatment of ED-SCLC, OS has not been significantly improved A few days ago, Journal of Clinical Oncology (JCO) published a double-blind phase III study online, showing that nivolumab combined with ipilimumab The monoclonal antibody is used for the maintenance treatment of extensive-stage small cell lung cancer (ED-SCLC), and does not significantly prolong the overall survival (OS).
-
Singapore's first commercialized CAR-T therapy!
Time of Update: 2021-03-22
com/genetherapy/" target="_blank">gene therapy products (CTGTP), the Singapore Health Sciences Authority (HSA) has approved Kymriah (tisagenlecleucel) as Singapore’s first commercial chimera Antigen receptor T cell (CAR-T) therapy.
-
ACG Guidelines: Screening for colorectal cancer starts at the age of 45!
Time of Update: 2021-03-22
2. It is recommended to carry out CRC screening for general risk individuals aged 45 to 49 years to reduce the incidence of advanced adenoma and CRC, and reduce the mortality rate of CRC (conditional recommendation; very low-quality evidence).
-
Why does cancer recur?
Time of Update: 2021-03-22
" Image source: 123RF When cancer cells are in a dormant state, it means that they no longer divide and are difficult to detect.
Researchers believe that there are several explanations for why cancer cells stop dividing and enter a dormant state.
-
How to break immune-related pneumonia?
Time of Update: 2021-03-22
In the Jinling Lung Cancer Network Forum, the immune-related adverse event (irAE) MDT team at the General Hospital of Tianjin Medical University brought a case of stage IIIB left lung squamous cell carcinoma with metastasis to the lock area, mediastinum, and hilar lymph nodes.
-
NEJM: The traditional cytogenetics alternative technology has been clinically verified, and the diagnosis rate and accuracy are better
Time of Update: 2021-03-22
Yan Hua Gene abnormalities in the Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, are particularly important for the diagnostic classification and prognostic risk assessment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
-
10-year follow-up results of the first phase 3 study: rituximab combined with high-dose chemotherapy did not improve the prognosis of patients with high-risk aggressive B-cell lymphoma
Time of Update: 2021-03-22
Fabian Frontzek, Germany, conducted a study to evaluate the use of high-dose chemotherapy + rituximab + autologous hematopoietic stem cell transplantation (ASCT) (R-MegaCHOEP protocol) in the first-line treatment of patients with high-risk aggressive B-cell lymphoma aged 18-60 ) The efficacy and safety of conventional chemotherapy + rituximab (R-CHOEP-14 regimen).
-
Professor Li Baosheng: In the age of immunotherapy, innovation and joint multi-dimensional optimization of clinical practice of esophageal cancer in my country
Time of Update: 2021-03-22
*Only for medical professionals to read for reference in the era of immunotherapy, the innovative drug Carrelizumab provides more choices for patients with esophageal cancer in my country, and combined immunotherapy with radiotherapy can further improve the therapeutic effect.
-
Gut: The risk of gastrointestinal cancer in patients with non-alcoholic fatty liver disease increases up to 2 times!
Time of Update: 2021-03-22
This study conducted a meta-analysis of observational studies to quantify the degree of association between NAFLD and the risk of extrahepatic cancer.
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
-
2021 EBMT | IKEMA study subgroup analysis: Kd scheme combined with Isatuximab will benefit MM patients after transplantation
Time of Update: 2021-03-22
01 Research Methods The study included MM patients who had previously received 1-3 lines of treatment, and randomly assigned them to receive the Kd regimen or the Isa-Kd regimen at a ratio of 3:2 until the patients developed disease progression or intolerable adverse events.
-
[Nature Sub-Journal] After this treatment of pancreatic cancer mice, the survival rate is significantly improved, and the spread of cancer is also reduced!
Time of Update: 2021-03-22
This article is converted Medicine original, reproduced please indicate the source Author: Yun Introduction: Recently, researchers found that mice high levels of integrin β5 were iRGD chemotherapy, the survival rate of pancreatic ductal adenocarcinoma in mice significantly improved cancer The diffusion rate is also reduced!
-
[2020 ASCO-GU] Changing with each passing day | The latest research progress of molecular imaging diagnosis in the field of prostate cancer
Time of Update: 2021-03-22
Abstract 36: Comparison of 18F-DCFPyL-PSMA PET and traditional imaging to detect pelvic lymph node metastasis in patients with locally advanced or oligometastatic prostate cancer [3] UW17009 is an exploration of neoadjuvant chemotherapy combined with ADT for advanced prostate cancer patients Clinical trials on efficacy and safety.
-
The screening age for lung cancer and colorectal cancer should be 5 years earlier, the younger the incidence, the more obvious the increase
Time of Update: 2021-03-22
Recently, the United States Preventive Services Task Force (USPSTF) and the American College of Gastroenterology (ACG) have successively released the latest editions of lung and colorectal cancer screening guidelines.
-
What should I do if CAR-T treatment for lymphoma patients fails?
Time of Update: 2021-03-22
Recently, the team of the Department of Hematology at the Second Affiliated Hospital of Zhejiang University School of Medicine published a paper in the Journal of Hematology & Oncology, demonstrating the use of the new CD19-PD-1/CD28-CAR-T technology for the rescue treatment of CD19-CAR-T After treatment fails, patients with diffuse large B-cell lymphoma (DLBCL) can achieve good results.
